Regencell Bioscience (NASDAQ:RGC) Trading Up 8% - Should You Buy?

Key Points

• Regencell's stock jumped about 8% intraday to roughly $31.13, but trading volume was light at ~64,990 shares — down about 83% from the average daily volume.
• Analyst sentiment is negative: Weiss Ratings reissued a "sell (e+)" and the stock's MarketBeat average rating is Sell.
• Several institutional investors recently initiated or increased positions (Squarepoint, BNP Paribas, XTX, Hudson Bay, Vident), yet institutional ownership remains very low at 0.13%; Regencell focuses on Traditional Chinese medicine treatments for neurocognitive disorders like ADHD and autism.

Regencell Bioscience Holdings Limited (NASDAQ:RGC - Get Free Report)'s stock price was up 8% during mid-day trading on Monday . The stock traded as high as $30.71 and last traded at $31.1320. Approximately 64,990 shares traded hands during mid-day trading, a decline of 83% from the average daily volume of 393,136 shares. The stock had previously closed at $28.82.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a "sell (e+)" rating on shares of Regencell Bioscience in a research note on Friday, March 27th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, Regencell Bioscience currently has an average rating of "Sell".

Regencell Bioscience Trading Up 9.2%

The company has a 50 day moving average of $27.05 and a two-hundred day moving average of $22.42.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of RGC. Squarepoint Ops LLC bought a new position in Regencell Bioscience during the second quarter valued at about $1,701,000. BNP Paribas Financial Markets bought a new position in Regencell Bioscience during the second quarter valued at about $768,000. XTX Topco Ltd bought a new position in Regencell Bioscience during the third quarter valued at about $598,000. Hudson Bay Capital Management LP bought a new position in Regencell Bioscience during the fourth quarter valued at about $275,000. Finally, Vident Advisory LLC boosted its stake in Regencell Bioscience by 65.7% during the fourth quarter. Vident Advisory LLC now owns 29,934 shares of the company's stock valued at $629,000 after buying an additional 11,866 shares in the last quarter. Institutional investors own 0.13% of the company's stock.

Regencell Bioscience Company Profile

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.